PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
September 14, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
June 05, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
January 17, 2023 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company...
PathMaker Neurosystems Receives $100,000 START Award from MassVentures
June 08, 2022 07:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
PathMaker Neurosystems Initiates U.S. Multi-Center Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity
March 07, 2022 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, March 07, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Awarded CERF Medical Electronics Prize for Amyotrophic Lateral Sclerosis
February 07, 2022 06:00 ET
|
PathMaker Neurosystems Inc.
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
PathMaker Neurosystems Appoints Leading Neurotechnology Expert, John Donoghue, Ph.D., to Board of Directors
October 21, 2021 05:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Announces Completion of Pivotal European Clinical Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity
September 27, 2021 05:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 27, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Announces Receipt of NIH Grant For Application of its Non-Invasive Neuromodulation Technology to Amyotrophic Lateral Sclerosis (ALS)
September 20, 2021 13:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Welcomes Healthcare Veteran Terri Bresenham to Board of Directors
July 15, 2020 07:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, July 15, 2020 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing breakthrough non-invasive technology for the...